Amgen Inc. (NASDAQ:AMGN ) RBC Capital Markets Global Healthcare Conference May 21, 2025 9:00 AM ET Company Participants Justin Claeys - VP, IR Kave Niksefat - Senior Vice President of Global Marketing & Access Conference Call Participants Gregory Renza - RBC Capital Markets Gregory Renza Good morning everyone. Welcome back to 2025 RBC Global Healthcare Conference.
THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m.
A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's rival drug Praluent.
Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research and Development Conference Call Participants Tim Anderson - Bank of America Merrill Lynch Tim Anderso...
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have ri...
THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Life Sciences degree in recognition of his significant leadership contributions to the biotechnology field.
Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past few decades, and that the lion's share of market returns can be attributed to reinvested dividends and compounding. Those are excellent arguments for investing in dividend stocks and holding on to them for a long time.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.